{"entity":{"id":"nct05798819","kind":"trial","name":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervic","aka":[],"tldr":"A phase 3 trial of Zimberelimab run by Guangzhou Gloria Biosciences Co., Ltd. in cervical cancer, now recruiting.","summary":"A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT05798819 by Guangzhou Gloria Biosciences Co., Ltd., with 424 participants planned, started 2023-04-20. Conditions listed: Persistent, Recurrent, or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05798819","url":"https://clinicaltrials.gov/study/NCT05798819"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cervical","recurrent-metastatic-cervical-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["zimberelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05798819","phase":"3","setting":"A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate GLS-010 Plus Platinum-containing Chemotherapy With or Without Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer","sponsor":"Guangzhou Gloria Biosciences Co., Ltd.","participation":[{"nct":"NCT05798819","source":"https://clinicaltrials.gov/study/NCT05798819","fetchedAt":"2026-10-07T16:53:56.649Z","studySha256":"72b97b85768ccbe07f0fb9b6d18a09ce7c5c031273bc598d692fc436f96ea0d6","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-16","leadSponsor":"Guangzhou Gloria Biosciences Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":424,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-04-20","startedType":"actual","enrolled":424,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05798819/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"recurrent-metastatic-cervical-cancer","kind":"cancer","name":"Recurrent or metastatic cervical cancer","route":"/cancers/recurrent-metastatic-cervical-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"zimberelimab","kind":"drug","name":"Zimberelimab","route":"/drugs/zimberelimab/"}]}}